Clinical Management of Chronic Obstructive Pulmonary DiseaseStephen I. Rennard, Roberto Rodriguez-Roisin, Gerard Huchon, Nicolas Roche Since the publication of the first edition, chronic obstructive pulmonary disease (COPD), as a public health issue, has increased in line with the predictions of the World Health Organization and by the year 2020, will become one of the main killers of human life.With several important large scaled trials becoming available and our knowledge of COP |
Contents
UNDERSTANDING COPD AND ITS IMPACT | 1 |
Chapter 2 Smoking Cessation | 23 |
Histopathogenesis | 43 |
Chapter 4 COPD as a Systemic Disease | 67 |
ASSESSING COPD | 77 |
Chapter 6 Assessment of Symptoms and Quality of Life in the COPD Patient | 89 |
Chapter 7 Measuring Ventilatory and Respiratory Impairment in COPD | 119 |
Chapter 8 Imaging of Lung Morphology and Function in COPD | 133 |
Chapter 16 Phosphodiesterase 4 Inhibitors Mucolytics and Emerging Pharmacotherapies for COPD | 323 |
An Overview | 347 |
NONPHARMACOLOGICAL APPROACHES IN COPD | 371 |
Chapter 19 New Components of Pulmonary Rehabilitation in COPD | 385 |
Chapter 20 LongTerm Oxygen Therapy for the Patient with COPD | 397 |
Chapter 21 Noninvasive Ventilation in COPD | 419 |
Chapter 22 Surgical Therapy for COPD | 435 |
The Anesthesiologists View | 475 |
Chapter 9 Assessing the Systemic Consequences of COPD | 165 |
Chapter 10 The Pulmonary Vasculature of COPD | 189 |
Chapter 11 How the COPD Patient Should Be Assessed for Comorbities | 211 |
From Clinical Trials to RealWorld Practice | 239 |
PHARMACOLOGICAL TREATMENTS OF COPD | 263 |
Chapter 14 When Should We Use Glucocorticoids in COPD? | 281 |
Chapter 15 Treating and Preventing Infections | 297 |
Other editions - View all
Common terms and phrases
activity acute airflow airway arterial assessment associated benefit bronchodilator capacity cardiovascular cause cells changes Chest chronic obstructive pulmonary cigarette clinical combination comorbidities compared controlled COPD patients decrease diagnosis dyspnea edited effects emphysema endurance et al evaluation evidence exacerbations exercise factors failure FEV1 guidelines health status heart hospital impairment important improvement increased indicate individuals infection inflammation inhaled less levels limitation long-term lower lung disease lung function major measures mechanisms months mortality muscle NPPV obstructive pulmonary disease outcome oxygen oxygen therapy patients with chronic patients with COPD performed placebo predicted pressure prevalence prevention pulmonary hypertension pulmonary rehabilitation randomized recent reduction reported Respir Crit respiratory response risk scores severe showed shown significant smoking subjects suggest surgery symptoms systemic Table therapy Thorax treatment trial ventilation walking